Liu S, et al. IMPOWER 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. IASLC 2018, abstract PL02.07.
LORIS voorspelt respons op en overleving na behandeling met checkpointremmer
sep 2024 | Immuuntherapie